Introduction
Obesity is a major global health burden and contributes significantly to morbidity and mortality across both adult and pediatric populations. In the year 2000, more than 300 million adults were classified as obese worldwide, with approximately 115 million individuals from low- and middle-income countries affected by obesity-related comorbidities.1 The cornerstone of management includes lifestyle modification through dietary regulation and increased physical activity; however, long-term weight reduction remains largely unsuccessful, with sustained success rates reported between 2–20%. Pharmacological therapy, such as orlistat, is approved for long-term use but is frequently associated with gastrointestinal adverse effects. Bariatric surgery represents the most effective intervention for severe obesity; nevertheless, its high cost, perioperative risks, and accessibility limitations restrict its widespread application, highlighting the need for safer, cost-effective, and sustainable therapeutic alternatives.
In Ayurveda, obesity is described as Sthaulya, a disorder of disturbed metabolic homeostasis. Classical Ayurvedic management emphasizes Shodhana Karma (biopurification therapies) and Basti Karma (medicated enema) as principal therapeutic modalities, alongside oral interventions. However, these approaches are often limited by high treatment cost, requirement of hospitalization, restricted patient compliance, and prolonged treatment duration. Among Shodhana procedures, Shirovirechana (Nasya Karma) is considered relatively simple and more feasible in clinical practice. Despite its theoretical relevance, the role of Nasya Karma in Sthaulya has been minimally explored, with a paucity of indexed clinical evidence.
Mechanisms of action in obesity
Triphaladi oil is proposed to exert anti-obesity effects through multiple biological pathways. The herbal constituents demonstrate lipolytic and adipolytic activity, contributing to reduced adipogenesis and enhanced mobilization of stored lipids. Bioactive phytochemicals within Triphala, including gallic acid, ellagic acid, and chebulinic acid, exhibit antioxidant and anti-inflammatory properties, thereby reducing chronic low-grade inflammation associated with obesity-induced insulin resistance. Additionally, modulation of digestive and metabolic fire (Agni) is believed to improve nutrient assimilation and prevent Ama formation, which correlates with improved metabolic efficiency.
At a molecular level, experimental evidence suggests that Triphaladi formulations may influence lipid metabolism through regulation of peroxisome proliferator-activated receptors (PPAR-α and PPAR-γ), enhancing fatty acid oxidation and improving insulin sensitivity. Antioxidant-mediated suppression of reactive oxygen species further contributes to improved mitochondrial function and reduced adipocyte hypertrophy.
Panchakarma-based delivery modalities
Triphaladi oil is administered through selected Panchakarma procedures, primarily Basti (medicated enema), Nasya (nasal administration), and Abhyanga (therapeutic oleation massage), depending on patient constitution and disease severity.2
Basti therapy is considered the principal intervention for systemic disorders involving Vata-Kapha imbalance. Triphaladi oil administered via Basti is believed to exert systemic lipid-lowering effects through gut–liver axis modulation, improved intestinal metabolism, and enhanced elimination of metabolic toxins. Clinical observations suggest reductions in body weight, waist circumference, and serum lipid parameters following structured Basti regimens.
Nasya therapy facilitates drug delivery through the nasal route, potentially influencing hypothalamic regulation of appetite and neuroendocrine control of metabolism. It may also modulate autonomic balance, thereby indirectly affecting energy homeostasis and fat metabolism.
Abhyanga using Triphaladi oil enhances peripheral circulation, improves lymphatic drainage, and promotes local lipolysis, contributing to reduction in subcutaneous fat deposition and improved skin and tissue metabolism.3
Clinical outcomes and metabolic effects
Clinical studies evaluating Triphaladi oil–based Panchakarma interventions have reported significant reductions in anthropometric indices, including body mass index (BMI), waist–hip ratio, and body fat percentage. Improvements in lipid profile parameters such as total cholesterol, triglycerides, and low-density lipoprotein (LDL) have also been observed. In addition, enhanced insulin sensitivity and improved glycemic parameters have been documented in several observational and pilot studies.
These outcomes suggest a multi-targeted metabolic effect involving appetite regulation, lipid mobilization, improved insulin signaling, and reduction of systemic inflammation. The integrative nature of Panchakarma procedures may further potentiate the bioavailability and therapeutic efficacy of Triphaladi oil.
Safety and tolerability
Triphaladi oil–based interventions are generally well tolerated when administered under supervised Ayurvedic protocols. Reported adverse effects are minimal and may include transient gastrointestinal discomfort or mild procedural intolerance in some individuals. Proper patient selection, dose standardization, and adherence to classical procedural guidelines are essential to ensure safety. Current evidence does not indicate significant hepatotoxicity or nephrotoxicity, although systematic long-term safety data remain limited.
Conclusion
Triphaladi oil–based Panchakarma interventions demonstrate promising multi-modal therapeutic potential in obesity management through lipid modulation, anti-inflammatory effects, and metabolic regulation. While preliminary evidence supports clinical benefits, further high-quality studies are required to validate their role as evidence-based integrative therapies in obesity management.
References:
- Ofei F. Obesity - a preventable disease. Ghana Med J. 2005;39(3):98-101. https://pmc.ncbi.nlm.nih.gov/articles/PMC1790820/
- Singh SK, Swami P, Rajoria K. Effects of medicated enema and nasal drops using Triphaladi oil in the management of obesity - A pilot study. J Ayurveda Integr Med. 2020;11(2):173-176. doi:10.1016/j.jaim.2020.02.001. https://pmc.ncbi.nlm.nih.gov/articles/PMC7329708/
- Patil UA. A Comparative Clinical Study of Triphaladi Taila Abhyanga and Triphala Choorna Udhvartana in the management of Sthaulya. Journal of Ayurveda and Integrated Medical Sciences. 2018 Apr 30;3(02):15-22. https://jaims.in/jaims/article/view/375